Inspire Medical Systems (INSP)


Market Price (11/15/2026): $61.03 | Market Cap: $1.8 BilSector: Health Care | Industry: Health Care Equipment

Inspire Medical Systems (INSP)


Market Price (11/15/2026): $61.03
Market Cap: $1.8 Bil
Sector: Health Care
Industry: Health Care Equipment

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.7%, FCF Yield is 5.5%

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -17%

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11%

Megatrend and thematic drivers
Megatrends include Precision Medicine, Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Show more.

Weak multi-year price returns
2Y Excs Rtn is -96%, 3Y Excs Rtn is -127%

Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14%

Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 58x

Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -7.9%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 13%

Key risks
INSP key risks include [1] execution failures and legal challenges from its Inspire V product launch, Show more.

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.7%, FCF Yield is 5.5%
1 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -17%
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11%
3 Megatrend and thematic drivers
Megatrends include Precision Medicine, Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Show more.
4 Weak multi-year price returns
2Y Excs Rtn is -96%, 3Y Excs Rtn is -127%
5 Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14%
6 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 58x
7 Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -7.9%
8 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 13%
9 Key risks
INSP key risks include [1] execution failures and legal challenges from its Inspire V product launch, Show more.

INSP in ETFs

Weight = INSP's share of each fund

VTI0.00%
ITOT0.00%
IWM0.06%
IJR0.11%
VB0.03%
IJT0.23%
SLYG0.23%
IWO0.11%
+9 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/13/2026

Nov 4: up 7.6% in one day (S&P 500 up 1.7%)
The stock gained after analysts increased their forecasts for Inspire Medical Systems on November 3, following upbeat third quarter results. The company had reported strong third quarter earnings on November 2.

Up 91.7% from its May 15 low to Sep 18, down 20.4% since (S&P 500 up 3.6%)
The stock advanced throughout this period, driven by the company's strong second quarter 2026 financial results, raised 2026 guidance, and strategic growth plan. The largest daily gain on August 4 followed these announcements.

Nov 3: down 7.9% the day after its Nov 2 earnings report (S&P 500 up 0.3%)
The stock declined after the company announced its third quarter 2026 financial results on November 2, reporting significantly lower revenue, net income, and diluted EPS compared to a year earlier. While earnings per share beat estimates, net income was negative.

Show more
Prices as of 11/13/2026

Nov 4: up 7.6% in one day (S&P 500 up 1.7%)
The stock gained after analysts increased their forecasts for Inspire Medical Systems on November 3, following upbeat third quarter results. The company had reported strong third quarter earnings on November 2.

Up 91.7% from its May 15 low to Sep 18, down 20.4% since (S&P 500 up 3.6%)
The stock advanced throughout this period, driven by the company's strong second quarter 2026 financial results, raised 2026 guidance, and strategic growth plan. The largest daily gain on August 4 followed these announcements.

Nov 3: down 7.9% the day after its Nov 2 earnings report (S&P 500 up 0.3%)
The stock declined after the company announced its third quarter 2026 financial results on November 2, reporting significantly lower revenue, net income, and diluted EPS compared to a year earlier. While earnings per share beat estimates, net income was negative.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 21.7% change in INSP stock from 7/31/2026 to 11/14/2026 was primarily driven by a 59.7% change in the company's P/E Multiple.
(LTM values as of)731202611142026Change
Stock Price ($)50.2161.1021.7%
Change Contribution By: 
Total Revenues ($ Mil)915881-3.7%
Net Income Margin (%)14.3%11.4%-20.2%
P/E Multiple11.017.659.7%
Shares Outstanding (Mil)2929-0.8%
Cumulative Contribution21.7%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/14/2026
ReturnCorrelation
INSP21.7% 
Market (SPY)1.2%30.6%
Sector (XLV)16.6%19.9%

Fundamental Drivers

The 8.8% change in INSP stock from 4/30/2026 to 11/14/2026 was primarily driven by a 57.1% change in the company's P/E Multiple.
(LTM values as of)430202611142026Change
Stock Price ($)56.1461.108.8%
Change Contribution By: 
Total Revenues ($ Mil)912881-3.4%
Net Income Margin (%)15.9%11.4%-28.3%
P/E Multiple11.217.657.1%
Shares Outstanding (Mil)29290.0%
Cumulative Contribution8.8%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/14/2026
ReturnCorrelation
INSP8.8% 
Market (SPY)5.5%16.4%
Sector (XLV)30.4%25.3%

Fundamental Drivers

The -15.2% change in INSP stock from 10/31/2025 to 11/14/2026 was primarily driven by a -56.2% change in the company's P/E Multiple.
(LTM values as of)1031202511142026Change
Stock Price ($)72.0861.10-15.2%
Change Contribution By: 
Total Revenues ($ Mil)8618812.3%
Net Income Margin (%)6.2%11.4%85.4%
P/E Multiple40.017.6-56.2%
Shares Outstanding (Mil)30292.0%
Cumulative Contribution-15.2%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/14/2026
ReturnCorrelation
INSP-15.2% 
Market (SPY)11.8%17.9%
Sector (XLV)33.1%20.7%

Fundamental Drivers

The -58.5% change in INSP stock from 10/31/2023 to 11/14/2026 was primarily driven by a -75.5% change in the company's P/S Multiple.
(LTM values as of)1031202311142026Change
Stock Price ($)147.1661.10-58.5%
Change Contribution By: 
Total Revenues ($ Mil)52688167.5%
P/S Multiple8.22.0-75.5%
Shares Outstanding (Mil)29291.0%
Cumulative Contribution-58.5%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/14/2026
ReturnCorrelation
INSP-58.5% 
Market (SPY)87.0%23.8%
Sector (XLV)59.4%22.6%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
INSP Return22%9%-19%-9%-50%-34%-68%
Peers Return6%-7%-32%50%0%3%4%
S&P 500 Return27%-19%24%23%16%11%103%

Monthly Win Rates [3]
INSP Win Rate58%58%50%50%17%45% 
Peers Win Rate44%56%47%47%39%56% 
S&P 500 Win Rate75%42%67%75%67%45% 

Max Drawdowns [4]
INSP Max Drawdown-34%-45%-62%-50%-67%-60% 
Peers Max Drawdown-39%-44%-61%-31%-45%-29% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: PEN, GMED, NVCR, KMTS, NXGL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/13/2026 (YTD)

How Low Can It Go

EventINSPS&P 500
2023 SVB Regional Banking Crisis
  % Loss-16.4%-6.7%
  % Gain to Breakeven19.7%7.1%
  Time to Breakeven17 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-38.0%-24.5%
  % Gain to Breakeven61.3%32.4%
  Time to Breakeven205 days427 days
2020 COVID-19 Crash
  % Loss-49.2%-33.7%
  % Gain to Breakeven96.8%50.9%
  Time to Breakeven58 days140 days

Compare to PEN, GMED, NVCR, KMTS, NXGL

In The Past

Inspire Medical Systems's stock fell -4.2% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 4.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventINSPS&P 500
2022 Inflation Shock & Fed Tightening
  % Loss-38.0%-24.5%
  % Gain to Breakeven61.3%32.4%
  Time to Breakeven205 days427 days
2020 COVID-19 Crash
  % Loss-49.2%-33.7%
  % Gain to Breakeven96.8%50.9%
  Time to Breakeven58 days140 days

Compare to PEN, GMED, NVCR, KMTS, NXGL

In The Past

Inspire Medical Systems's stock fell -4.2% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 4.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Inspire Medical Systems (INSP)

Inspire Medical Systems (INSP) is a medical technology company focused on developing and commercializing minimally invasive solutions for patients with obstructive sleep apnea (OSA). Since its incorporation in 2007, the company has positioned itself as an innovator in addressing this common sleep disorder, offering an alternative to traditional treatments.

The company's core product is the Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. This implanted system works by gently stimulating the hypoglossal nerve to keep the airway open during sleep. Inspire Medical Systems is also engaged in developing a novel, closed-loop solution designed to continuously monitor a patient's breathing and deliver precisely timed hypoglossal nerve stimulation.

Inspire Medical Systems serves patients with moderate to severe obstructive sleep apnea. Its market reach spans both the United States and international geographies, providing a critical treatment option for individuals who may not tolerate or benefit from other OSA therapies.

AI Analysis | Feedback

Here are 1-2 brief analogies to describe Inspire Medical Systems (INSP):

  • Like a specialized Medtronic focused on treating sleep apnea.
  • The Cochlear Limited of sleep apnea treatment.

AI Analysis | Feedback

  • Inspire system: A neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea (OSA).
  • Novel closed-loop solution: A developing technology designed to continuously monitor a patient's breathing and deliver mild hypoglossal nerve stimulation to maintain an open airway.

AI Analysis | Feedback

Inspire Medical Systems (INSP) sells its Inspire system primarily to healthcare providers and facilities, which then use the technology to treat individual patients with obstructive sleep apnea (OSA).

The major categories of customers for Inspire Medical Systems are:

  1. Hospitals: Large medical institutions that perform a wide range of surgical procedures and treatments, including those for sleep disorders.
  2. Ambulatory Surgical Centers (ASCs): Facilities where surgical procedures that do not require an overnight hospital stay are performed, often offering a more cost-effective setting for device implantation.
  3. Specialized ENT (Ear, Nose, and Throat) Practices and Sleep Clinics: Medical practices and centers that specialize in the diagnosis and treatment of conditions related to the ear, nose, throat, and sleep disorders, where Inspire system implantations are performed.

AI Analysis | Feedback

null

AI Analysis | Feedback

The management team of Inspire Medical Systems (INSP) consists of the following members:

Timothy P. Herbert, Chairman, President and Chief Executive Officer

Mr. Herbert is the founder of Inspire Medical Systems, establishing the company in 2007. He has served as President and CEO since its inception and assumed the role of Chairman of the Board in May 2024. Before founding Inspire, Mr. Herbert spent 11 years, from 1996 to 2007, at Medtronic plc, where he held various management positions across product development, clinical research, sales, marketing, and healthcare reimbursement. He was instrumental in developing Inspire's core neurostimulation technology and leading its capital formation strategies. Mr. Herbert holds a B.S. in Electrical Engineering from North Dakota State University and an M.B.A. from the University of St. Thomas.

Matt Osberg, Executive Vice President and Chief Financial Officer

Mr. Osberg was appointed Executive Vice President and Chief Financial Officer, effective January 19, 2026. He brings over 20 years of experience in financial leadership. Prior to joining Inspire, Mr. Osberg served as Executive Vice President and CFO at Apogee Enterprises, Inc. His career also includes CFO positions at Helen of Troy, Ltd. and various finance leadership roles at Best Buy, Inc. He began his career at Ernst & Young LLP. Mr. Osberg has a background primarily outside of the medical technology industry.

Bryan K. Phillips, SVP, General Counsel, Chief Compliance Officer and Corporate Secretary

Mr. Phillips joined Inspire Medical Systems in January 2021. Before his role at Inspire, he served as Chief Legal Officer at Cerevel Therapeutics Holdings, Inc. from 2019 to 2021. He also spent 14 years at Surmodics, Inc., a publicly traded medical technology company, holding various positions including Senior Vice President, Legal and Human Resources, General Counsel, and Secretary. Earlier in his career, he was patent counsel at Guidant Corporation's Cardiac Rhythm Management Group (now part of Boston Scientific) and began his legal career at a Minneapolis-based intellectual property law firm. Mr. Phillips holds a B.S. in Mechanical Engineering from the University of Kansas and a J.D. from the University of Minnesota Law School.

Carlton W. Weatherby, Chief Strategy and Growth Officer

Mr. Weatherby has been Inspire Medical Systems' Chief Strategy and Growth Officer since January 2024. Prior to joining Inspire, he served as the Chief Commercial Officer at AliveCor, Inc., a medical device company, from July 2021 to December 2023. He also held roles as President, Commercial Operations, and Chief Commercial Officer at Intersect ENT, Inc., a medical technology company, from October 2017 to July 2021, and as Vice President, Sales & Marketing, ENT at Smith & Nephew plc from January 2013 to October 2017. Mr. Weatherby received his B.S. in Biology from West Chester University.

John C. Rondoni, Chief Product & Innovation Officer

Mr. Rondoni has served as Inspire Medical Systems' Chief Product & Innovation Officer since January 2025. He has been with Inspire since January 2010, holding various positions including Vice President of Product Development, Operations & Quality. Before joining Inspire, Mr. Rondoni spent 11 years at Medtronic, Inc., where he held leadership roles in research and development. He began his career at Boston Scientific, Inc. in research and development. Mr. Rondoni holds a B.S. in Bioengineering from Syracuse University and an M.S. in Biomedical Engineering from the University of Alabama, Birmingham.

AI Analysis | Feedback

The key risks to Inspire Medical Systems (INSP) primarily revolve around reimbursement challenges, increasing competition, and operational hurdles related to product launches.

  1. Reimbursement Uncertainty and Operational Challenges with New Product Launches: Inspire Medical Systems faces significant risks due to evolving and uncertain reimbursement policies, particularly concerning its latest device, Inspire V. There have been issues with CMS coding, including a shift from CPT code 64568 to 64582, which could reduce professional fees. A notable concern was the reversal of a key Medicare reimbursement code by administrative contractors, which negatively impacted reimbursement rates and created uncertainty about future revenue growth. Furthermore, the company is facing securities fraud lawsuits alleging that it concealed critical operational failures during the Inspire V launch, such as incomplete training and onboarding for treatment centers, delays in software updates for Medicare claims processing, and an excess inventory of the older Inspire IV device, all of which led to a significant reduction in 2025 earnings guidance.

  2. Increasing Competition from Alternative Therapies and Competitors: The market for obstructive sleep apnea (OSA) treatment is becoming more competitive. Inspire faces competition from established players like ResMed, which dominates the CPAP machine market (the standard first-line treatment for OSA). Moreover, emerging alternative therapies pose a threat, including oral appliance therapies, new pharmaceutical treatments like GLP-1 drugs (e.g., Lilly's Tirzepatide, which can improve sleep quality in obese patients), and Apnimed's AD109. These alternatives could potentially dilute Inspire's market opportunity, especially for its third-line treatment offering.

  3. Healthcare Provider Capacity Constraints: The growth and adoption of Inspire's hypoglossal nerve stimulation therapy are heavily reliant on ear, nose, and throat (ENT) surgeons who perform the implantation procedures. A potential constraint on the company's growth is the capacity of the ENT workforce. If the growth in the number of ENT surgeons or their availability to perform these procedures does not keep pace with the demand for Inspire's device, it could cap the company's growth potential.

AI Analysis | Feedback

The emergence of competing hypoglossal nerve stimulation devices represents a clear emerging threat. Specifically, Nyxoah's Genio system, which received FDA approval in August 2023, is a direct competitor to Inspire's core technology. Nyxoah's system is also designed for obstructive sleep apnea and offers a battery-free, leadless, and minimally invasive solution, which could differentiate it in the market and challenge Inspire's market share and first-mover advantage.

AI Analysis | Feedback

Inspire Medical Systems (INSP) addresses a significant market for its neurostimulation technology designed for patients with obstructive sleep apnea (OSA). The company's main product, the Inspire system, provides a minimally invasive solution for individuals with moderate to severe OSA, particularly those who cannot tolerate continuous positive airway pressure (CPAP) machines. The addressable market for Inspire's therapy is estimated to be over $10 billion in the U.S. alone. This market primarily targets the subset of patients with OSA who are unable to use or adhere to traditional CPAP therapy. Approximately 700,000 patients annually fail to comply with CPAP therapy, with Inspire estimating that about 500,000 of these patients are eligible for their therapy, creating a substantial addressable market. In broader terms, obstructive sleep apnea affects 17 million Americans and an additional 83 million people globally. The U.S. sleep apnea implants market, which includes Inspire's technology, was valued at USD 840 million in 2024 and is projected to grow to USD 4.3 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 17.4% from 2025 to 2034. The global sleep apnea devices market was valued at USD 10.30 billion in 2025 and is projected to reach USD 22.87 billion by 2034. North America held the largest share of this market, accounting for 49.55% in 2025.

AI Analysis | Feedback

Inspire Medical Systems (INSP) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market dynamics:

  1. Successful launch and adoption of new product generations: The company anticipates continued revenue growth from the successful launch and strong acceptance of its fifth-generation Inspire V system, which was a significant contributor to revenue in late 2025 and is expected to fuel momentum in 2026.
  2. Increased utilization at existing implanting centers: A primary driver of U.S. revenue growth has been, and is expected to continue to be, higher utilization of the Inspire therapy at already established medical centers.
  3. Expansion of implanting centers and sales territories: Inspire Medical Systems consistently focuses on activating new U.S. medical centers and expanding its sales organization by creating new sales territories, thereby increasing market penetration and access to its therapy.
  4. Direct-to-consumer marketing programs: The company's ongoing direct-to-consumer marketing initiatives are expected to continue raising awareness and driving patient interest, contributing to overall demand and revenue growth.
  5. Potential positive reimbursement developments: Inspire Medical Systems sees potential upside from ongoing reimbursement developments, although these have not yet been fully factored into current growth forecasts. Recent clarifications regarding CPT codes for the Inspire V procedure could influence future revenue.

AI Analysis | Feedback

Share Repurchases

  • Inspire Medical Systems' Board of Directors authorized a share repurchase program of up to $200 million on August 11, 2025, which is set to expire on August 7, 2027.
  • In 2025, the company completed $175 million in share repurchases.
  • Previously, on August 6, 2024, the Board authorized the repurchase of up to $150 million of common stock, a program that was the first of its kind for Inspire and set to expire on August 5, 2026.

Share Issuance

  • As of April 30, 2025, Inspire Medical Systems had 29,493,924 shares of common stock outstanding.
  • For 2026, the estimated weighted average diluted shares outstanding are approximately 29.4 million.
  • In February 2026, an executive acquired 2,196 shares through vested performance stock units, and another officer acquired 2,400 shares from similar vested units, along with 15,958 additional shares via a new stock award.

Capital Expenditures

  • For the upcoming year, 2026, Inspire Medical Systems anticipates capital expenditures to range between $45 million and $50 million.
  • The company made significant investments in 2025 to build its commercial infrastructure, increase patient marketing, and expand medical education expenses, particularly to support the U.S. launch of its Inspire V neurostimulation system.

Better Bets vs. Inspire Medical Systems (INSP)

Latest Trefis Analyses

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

INSPPENGMEDNVCRKMTSNXGLMedian
NameInspire .Penumbra Globus M.NovoCure Kestra M.NexGel  
Mkt Price61.03321.0072.1211.7929.063.9645.05
Mkt Cap1.812.69.71.4--5.7
Rev LTM8811,5603,140725-12881
Op Inc LTM16189717-125--516
FCF LTM98200757-25--1098
FCF 3Y Avg78162543-56--678
CFO LTM135261926-1--3135
CFO 3Y Avg116206685-24--3116

Growth & Margins

INSPPENGMEDNVCRKMTSNXGLMedian
NameInspire .Penumbra Globus M.NovoCure Kestra M.NexGel  
Rev Chg LTM-0.2%17.0%13.4%12.9%-3.4%12.9%
Rev Chg 3Y Avg16.4%16.2%42.4%12.9%-70.1%16.4%
Rev Chg Q-7.9%15.6%-0.7%15.7%-27.8%15.6%
QoQ Delta Rev Chg LTM-2.0%3.7%-0.2%3.7%-7.1%3.7%
Op Inc Chg LTM-57.1%9.5%65.5%29.5%--77.6%9.5%
Op Inc Chg 3Y Avg80.7%52.4%64.9%15.8%--22.3%52.4%
Op Mgn LTM1.8%12.1%22.8%-17.2%--44.8%1.8%
Op Mgn 3Y Avg2.6%10.6%15.1%-24.1%--48.6%2.6%
QoQ Delta Op Mgn LTM-4.2%-0.3%1.4%4.9%--13.4%-0.3%
CFO/Rev LTM15.3%16.7%29.5%-0.1%--26.6%15.3%
CFO/Rev 3Y Avg13.6%15.1%24.0%-4.0%--37.7%13.6%
FCF/Rev LTM11.1%12.8%24.1%-3.4%--81.6%11.1%
FCF/Rev 3Y Avg9.1%11.9%19.0%-9.0%--61.6%9.1%

Valuation

INSPPENGMEDNVCRKMTSNXGLMedian
NameInspire .Penumbra Globus M.NovoCure Kestra M.NexGel  
Mkt Cap1.812.69.71.4--5.7
P/S2.08.13.11.9--2.5
P/Op Inc112.066.813.5-11.1--40.2
P/EBIT57.660.513.5-15.3--35.6
P/E17.580.617.3-11.3--17.4
P/CFO13.148.510.4-1,907.1--11.8
Total Yield5.7%1.2%5.8%-8.8%--3.5%
Dividend Yield0.0%0.0%0.0%0.0%--0.0%
FCF Yield 3Y Avg3.3%1.6%6.0%-3.5%--2.5%
D/E0.00.00.00.2--0.0
Net D/E-0.2-0.0-0.0-0.2---0.1

Returns

INSPPENGMEDNVCRKMTSNXGLMedian
NameInspire .Penumbra Globus M.NovoCure Kestra M.NexGel  
1M Rtn-10.3%0.3%-5.5%-14.8%14.1%-27.5%-7.9%
3M Rtn6.9%-1.8%-16.0%-30.4%3.7%32.0%0.9%
6M Rtn52.4%-0.4%-5.9%-32.9%46.6%32.0%15.8%
12M Rtn-29.7%15.2%-14.1%3.6%16.7%32.0%9.4%
3Y Rtn-54.1%49.3%56.6%-7.9%33.1%32.0%32.5%
1M Excs Rtn-11.4%1.5%-6.9%-16.6%3.0%-21.9%-9.1%
3M Excs Rtn8.3%-0.3%-13.7%-31.1%6.1%33.7%2.9%
6M Excs Rtn49.5%-3.3%-8.7%-35.8%43.7%29.1%12.9%
12M Excs Rtn-44.1%3.3%-26.1%-7.4%-2.9%20.6%-5.2%
3Y Excs Rtn-126.8%-5.4%-16.6%-75.8%-41.9%-43.4%-42.6%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Inspire system912803625  
Single Segment   408233
Total912803625408233


Price Behavior

null
INSP Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta1.120.852.320.771.011.06
Up Beta-4.40-1.934.640.991.681.38
Down Beta1.251.380.721.080.310.85
Up Capture130%148%328%71%81%36%
Bmk +ve Days12182862130427
Stock +ve Days10203063123369
Down Capture136%69%113%38%107%105%
Bmk -ve Days10253664121325
Stock -ve Days12233463128380

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with INSP
INSP-32.9%70.1%-0.29-
Sector ETF (XLV)25.8%16.8%1.1819.9%
Equity (SPY)11.6%13.7%0.5419.9%
Gold (GLD)-7.9%28.9%-0.2916.3%
Commodities (DBC)33.8%21.3%1.26-4.9%
Real Estate (VNQ)10.7%14.2%0.4717.4%
Bitcoin (BTCUSD)-33.0%43.7%-0.7915.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with INSP
INSP-26.1%61.1%-0.24-
Sector ETF (XLV)9.1%15.4%0.3930.2%
Equity (SPY)11.5%17.3%0.4935.5%
Gold (GLD)15.9%19.2%0.667.5%
Commodities (DBC)7.8%19.6%0.285.3%
Real Estate (VNQ)1.3%18.9%-0.0428.8%
Bitcoin (BTCUSD)2.2%51.6%0.2320.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with INSP
INSP9.4%60.4%0.43-
Sector ETF (XLV)13.0%16.8%0.6437.9%
Equity (SPY)15.5%18.0%0.7340.6%
Gold (GLD)11.1%16.6%0.547.1%
Commodities (DBC)7.6%18.1%0.3310.7%
Real Estate (VNQ)6.3%20.7%0.2632.8%
Bitcoin (BTCUSD)58.4%66.2%0.9816.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity4.1 Mil
Short Interest: % Change Since 10152026-7.8%
Average Daily Volume0.6 Mil
Days-to-Cover Short Interest6.6 days
Basic Shares Quantity28.9 Mil
Short % of Basic Shares14.3%

Earnings Returns History

Updated 11/11/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/2/2026-7.9%-4.3% 
8/3/202622.8%14.4%17.8%
5/4/2026-12.0%-21.0%-26.3%
2/11/2026-12.5%-12.4%-14.1%
11/3/202515.3%16.8%90.0%
8/4/2025-32.4%-38.7%-34.1%
5/5/20252.0%-1.4%-13.1%
2/10/20251.7%-0.5%-10.2%
...
SUMMARY STATS   
# Positive13129
# Negative121315
Median Positive7.0%7.5%19.9%
Median Negative-11.3%-16.7%-13.2%
Max Positive31.8%39.1%90.0%
Max Negative-33.5%-38.7%-36.3%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/2/2026-7.9%-4.3% 
8/3/202622.8%14.4%17.8%
5/4/2026-12.0%-21.0%-26.3%
2/11/2026-12.5%-12.4%-14.1%
11/3/202515.3%16.8%90.0%
8/4/2025-32.4%-38.7%-34.1%
5/5/20252.0%-1.4%-13.1%
2/10/20251.7%-0.5%-10.2%
11/4/20243.3%4.8%2.2%
8/6/202428.1%30.7%34.2%
5/7/2024-33.5%-35.4%-36.3%
2/6/2024-10.5%-16.7%-8.9%
11/7/2023-19.7%-17.7%-0.5%
8/1/2023-4.5%-15.8%-18.3%
5/2/20237.0%12.0%17.5%
1/9/2023-1.5%4.2%1.2%
11/1/20227.5%5.4%24.7%
8/2/20220.7%-2.3%-11.7%
5/3/2022-3.1%-27.6%-13.2%
2/8/20222.0%0.0%-4.6%
11/2/2021-1.4%2.0%-18.2%
8/3/202112.8%0.6%19.9%
5/4/2021-12.6%-20.6%-26.8%
2/23/20214.9%9.5%-12.3%
11/2/202031.8%39.1%57.3%
SUMMARY STATS   
# Positive13129
# Negative121315
Median Positive7.0%7.5%19.9%
Median Negative-11.3%-16.7%-13.2%
Max Positive31.8%39.1%90.0%
Max Negative-33.5%-38.7%-36.3%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/02/202610-Q
06/30/202608/03/202610-Q
03/31/202605/04/202610-Q
12/31/202502/13/202610-K
09/30/202511/03/202510-Q
06/30/202508/04/202510-Q
03/31/202505/05/202510-Q
12/31/202402/10/202510-K
09/30/202411/04/202410-Q
06/30/202408/06/202410-Q
03/31/202405/07/202410-Q
12/31/202302/09/202410-K
09/30/202311/07/202310-Q
06/30/202308/01/202310-Q
03/31/202305/02/202310-Q
12/31/202202/10/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/02/202610-Q
06/30/202608/03/202610-Q
03/31/202605/04/202610-Q
12/31/202502/13/202610-K
09/30/202511/03/202510-Q
06/30/202508/04/202510-Q
03/31/202505/05/202510-Q
12/31/202402/10/202510-K
09/30/202411/04/202410-Q
06/30/202408/06/202410-Q
03/31/202405/07/202410-Q
12/31/202302/09/202410-K
09/30/202311/07/202310-Q
06/30/202308/01/202310-Q
03/31/202305/02/202310-Q
12/31/202202/10/202310-K
09/30/202211/01/202210-Q
06/30/202208/02/202210-Q
03/31/202205/03/202210-Q
12/31/202102/15/202210-K
09/30/202111/02/202110-Q
06/30/202108/03/202110-Q
03/31/202105/04/202110-Q
12/31/202002/24/202110-K
09/30/202011/02/202010-Q
06/30/202008/04/202010-Q
03/31/202005/05/202010-Q
12/31/201902/25/202010-K

Recent Forward Guidance

Updated 11/3/2026

Latest: Q3 2026 Earnings Reported 11/2/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 Legal fees per diluted shareReported0.290.30.31   
2026 Legal settlement per diluted shareReported 0.18    
2026 Restructuring charges per diluted shareReported 0.64    
2026 Share forfeitures per diluted shareReported -0.16    
2026 RevenueReported850.00 Mil855.00 Mil860.00 Mil0.0% AffirmedGuidance: 855.00 Mil for 2026
2026 Adjusted Operating MarginReported4.5%5.0%5.5% 0.0%AffirmedGuidance: 5.0% for 2026
2026 Effective Tax RateReported120.0%147.5%175.0%   
2026 Adjusted Effective Tax RateReported33.0%33.5%34.0%   
2026 Tax impact of stock-based compensation per diluted shareReported0.550.570.59   
2026 Diluted EPSReported-0.36-0.23-0.184.0% LoweredGuidance: -0.13 for 2026
2026 Adjusted Diluted EPSReported1.21.31.44.0% RaisedGuidance: 1.25 for 2026
2026 Weighted Average Diluted Shares OutstandingReported 28.90 Mil    
2026 Capital ExpendituresReported35.00 Mil37.50 Mil40.00 Mil0.0% AffirmedGuidance: 37.50 Mil for 2026


Prior: Q2 2026 Earnings Reported 8/3/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported835.00 Mil855.00 Mil875.00 Mil0.6% RaisedGuidance: 850.00 Mil for 2026
2026 Adjusted Operating MarginReported4.0%5.0%6.0% 2.0%RaisedGuidance: 3.0% for 2026
2026 Diluted EPSReported-0.42-0.130.17-136.2% LoweredGuidance: 0.35 for 2026
2026 Adjusted Diluted EPSReported1.051.251.4525.0% RaisedGuidance: 1 for 2026
2026 Capital ExpendituresReported35.00 Mil37.50 Mil40.00 Mil-11.8% LoweredGuidance: 42.50 Mil for 2026

Q1 2026 Earnings Reported 5/4/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported825.00 Mil850.00 Mil875.00 Mil-12.8% LoweredGuidance: 975.00 Mil for 2026
2026 Adjusted Operating MarginReported2.0%3.0%4.0% -4.0%LoweredGuidance: 7.0% for 2026
2026 Diluted EPSReported0.070.350.62-77.3% LoweredGuidance: 1.52 for 2026
2026 Adjusted Diluted EPSReported0.7511.25-52.4% LoweredGuidance: 2.1 for 2026
2026 Capital ExpendituresReported40.00 Mil42.50 Mil45.00 Mil-10.5% LoweredGuidance: 47.50 Mil for 2026

Q4 2025 Earnings Reported 2/11/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported950.00 Mil975.00 Mil1.00 Bil7.7% Higher NewGuidance: 905.00 Mil for 2025
2026 Revenue GrowthReported4.0%7.0%10.0% -5.5%Lower NewGuidance: 12.5% for 2025
2026 Adjusted Operating MarginReported6.0%7.0%8.0% -78.0%Lower NewGuidance: 85.0% for 2025
2026 Net Income per Diluted ShareReported1.231.521.8160.0% Higher NewGuidance: 0.95 for 2025
2026 Adjusted Net Income per Diluted ShareReported1.852.12.35121.1% Higher NewGuidance: 0.95 for 2025
2026 Capital ExpendituresReported45.00 Mil47.50 Mil50.00 Mil   

Insider Activity

Updated 9/2/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Kelly, Jason PSee RemarksDirectSell811202659.5596357,3471,130,557Form
2Rondoni, JohnSee RemarksDirectSell519202643.282,641114,3021,175,701Form
3Rondoni, JohnSee RemarksDirectSell515202643.0170030,1071,281,956Form
4McCormick, ShawnDirectSell511202645.3169631,5361,255,631Form
5Rondoni, JohnSee RemarksDirectSell1122026100.0010910,9001,379,700Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Kelly, Jason PSee RemarksDirectSell811202659.5596357,3471,130,557Form
2Rondoni, JohnSee RemarksDirectSell519202643.282,641114,3021,175,701Form
3Rondoni, JohnSee RemarksDirectSell515202643.0170030,1071,281,956Form
4McCormick, ShawnDirectSell511202645.3169631,5361,255,631Form
5Rondoni, JohnSee RemarksDirectSell1122026100.0010910,9001,379,700Form
6McCormick, ShawnDirectSell12042025139.001,200166,8003,453,594Form
7McCormick, ShawnDirectSell12012025127.482,000254,9603,320,344Form
8Curet, MyriamDirectSell1124202577.284309260,032Form
9Curet, MyriamDirectSell11242025153.222306516,211Form
10Curet, MyriamDirectBuy11242025148.261148499,791Form
11Curet, MyriamDirectBuy11242025163.844655552,137Form
12Buchholz, RichardChief Financial OfficerDirectSell902202593.3911,0001,027,2904,190,129Form
Core Cache Last Updated: 11/14/2026